Expanded Access Use of T89 in An Intermediate-size Patients Population for the Treatment of Severe "Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)" Infection Disease Patients (COVID-19)
Latest Information Update: 10 Aug 2023
At a glance
- Drugs T 89 (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Expanded access; Therapeutic Use
- Sponsors Tasly Pharmaceuticals, Inc.
- 04 Aug 2023 Status has been changed to completed.
- 02 Dec 2020 New trial record